Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P08473

UPID:
NEP_HUMAN

ALTERNATIVE NAMES:
Atriopeptidase; Common acute lymphocytic leukemia antigen; Enkephalinase; Neutral endopeptidase 24.11; Skin fibroblast elastase

ALTERNATIVE UPACC:
P08473; A8K6U6; D3DNJ9; Q3MIX4

BACKGROUND:
The protein Neprilysin, also referred to as Neutral endopeptidase 24.11, exhibits a broad specificity towards peptides involved in blood pressure regulation and pain modulation. It is biologically significant in the destruction of opioid peptides and the degradation of natriuretic factors, contributing to cardiovascular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given Neprilysin's critical function in modulating peptides that affect neurodegeneration and cardiovascular health, exploring its mechanisms offers promising avenues for developing treatments for related diseases. Its role in Charcot-Marie-Tooth disease and Spinocerebellar ataxia 43 underscores the therapeutic potential of targeting Neprilysin.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.